Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores
October 14 2022 - 9:18AM
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that
under a General Merchandise Supplier Agreement with Walmart, the
Company’s Aware® Breast Self Exam device will now be sold in over
2400 Walmart’s retail stores. In July, the Company announced that
Walmart had begun selling the Aware product online through
Walmart.com. Walmart has now determined to also sell Aware
in-store, at approximately 50% of their retail store locations.
Biomerica has received and shipped an Initial stocking order from
Walmart, and the product should be on store shelves within weeks.
The product retails for $19.95.
The Biomerica FDA cleared Aware® Breast Self
Exam device is a revolutionary way for women to enhance tactile
sensitivity to detect changes or irregularities in breast tissue,
making breast self-exams easy and convenient. The
Aware® device can facilitate an effective
self-exam and can serve as a reminder to perform a breast self-exam
every month.
Zack Irani, Chief Executive Officer of
Biomerica, commented, “Overcoming breast cancer is all about early
detection. Our unique product provides a tool to assist women in
potentially detecting breast abnormalities early. As one of the
largest retailers in the world, Walmart provides unmatched
visibility and distribution for this potentially life-saving
product. We look forward to supporting Walmart in the roll-out,
ensuring that as many women as possible have access to Aware®.”
Breast Cancer is the most common cancer among
women. About 80% of breast cancers are detected because women
themselves notice changes in their breasts[3], highlighting the
important role that each woman can play in her own health.
Unfortunately, every woman is potentially at risk, as over 70% of
women diagnosed have no family history of breast cancer. Currently,
there is no way to prevent breast cancer, so detecting the disease
early is key to effective treatment. Early detection significantly
improves the chances that breast cancer can be diagnosed and
treated successfully. Survival rates are as high as 99% when the
cancer is found early and is still localized in the breast.
However, if the cancer has spread to the regional lymph nodes, the
5-year survival rate is 86%. [1,2] A Breast Self-Examination (BSE)
is not a replacement for regular medical visits and periodic
ultrasound or mammography. All three steps are important to finding
breast cancer early. The importance of early detection cannot be
overemphasized.
For further information about the
Aware® Breast Self Exam Product, please visit
https://AwareBSE.com.
Biomerica is in discussions with other partners
for distribution of the Aware® Breast Self Exam
product in the USA and markets outside of the U.S.
About Biomerica (NASDAQ:
BMRA)
Biomerica, Inc. (www.biomerica.com) is a global
biomedical technology company that develops, patents, manufactures
and markets advanced diagnostic and therapeutic products used at
the point of care (in home and in physicians’ offices) and in
hospital/clinical laboratories for detection and/or treatment of
medical conditions and diseases. The Company’s products are
designed to enhance the health and well-being of people, while
reducing total healthcare costs. Biomerica’s primary focus is on
gastrointestinal and inflammatory diseases where the Company has
multiple diagnostic and therapeutic products in development.
1.
https://www.webmd.com/breast-cancer/guide/breast-cancer-survival-rates.
Accessed 08 July 2022 2.
https://www.cancer.net/cancer-types/breast-cancer/statistics.
Accessed 08 July 20223.
https://www.pinkribbon-deutschland.de/vorsorge-fakten/fakten,
accessed 02 AUG 2022
The Private Securities Litigation Reform Act of
1995 provides a "safe harbor" for forward-looking statements.
Certain information included in this press release (as well as
information included in oral statements or other written statements
made or to be made by Biomerica) contains statements that are
forward-looking, such as statements relating to the efficacy of the
Company’s Aware® Breast Self-Exam device and other
tests, FDA clearance of the Company’s products, possible online
and/or in-store offering and sale of the Aware®
Breast Self-Exam device at Walmart and other potential distributors
and retailers, the rapidity of testing results, negotiations with
international distribution partners, uniqueness of the Company’s
products, test result accuracy of products, pricing of the
Company’s test kits, demand for domestic or international orders,
potential revenues from the sale of current or future products,
availability of the Company’s Aware® Breast
Self-Exam device and other test kits, and patent protection on any
of the Company’s products or technologies. Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future, including,
without limitation: results of studies testing the efficacy of the
Company’s tests and other products; regulatory approvals necessary
prior to commercialization any of the Company’s products;
availability of the Company’s test kits and other products;
capacity, resource and other constraints on our suppliers;
dependence on our third party manufacturers; dependence on
international shipping carriers; governmental import/export
regulations; demand for our various tests and other products;
competition from other similar products and from competitors that
have significantly more financial and other resources available to
them; governmental virus control regulations that make it difficult
or impossible for the company to maintain current operations; the
Company’s ability to comply with current and future regulations in
the countries where our products are made and sold and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies. Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. Additionally, potential risks
and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion
plans, downturns in international and or national economies, the
Company's ability to raise additional capital, the competitive
environment in which the Company will be competing, and the
Company's dependence on strategic relationships. The Company is
under no obligation to update any forward-looking statements after
the date of this release.
Corporate Contact:Investor
RelationsInvestor@biomerica.com949-645-2111
Source: Biomerica, Inc.
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024